ClinicalTrialsFinder
RecruitingNCT04904146

Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.

Sponsor

Lund University Hospital

Enrollment

120 participants

Start Date

Apr 2, 2021

Study Type

OBSERVATIONAL

Conditions

Mycosis FungoidesSezary Syndrome

Summary

A translational study for identification of prognostic and treatment-predictive biomarkers in Mycosis fungoides and Sézary syndrome.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Inclusion Criteria6

  • Age 18-100 years
  • Histologically confirmed (according to the World Health Organization (WHO)/EORTC classification) MF/SS stages I-IV
  • WHO performance status 0 -3
  • Absence of psychiatric illness or condition which could interfere with the subjects' ability to understand the requirements of the study.
  • Written informed consent according to International Conference on Harmonization (ICH)/(Good Clinical Practice (GCP), and Swedish regulations
  • No minimum or maximum required routine laboratory data

Interventions

DIAGNOSTIC_TESTBlood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.

The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.

Locations(1)

Lund University Hospital

Lund, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04904146

Related Trials

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

NCT065084632 locations

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

NCT070554771 location

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

NCT062078121 location

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

NCT053577941 location

Extracorporeal Photopheresis in Sezary Syndrome

NCT051575813 locations